Lin Y.-T.CHIA-YU CHU2019-12-042019-12-0420190169-5002https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062087200&doi=10.1016%2fj.lungcan.2018.12.030&partnerID=40&md5=d7475747d782370a5d90fcae337e3571https://scholars.lib.ntu.edu.tw/handle/123456789/434859[SDGs]SDG3epidermal growth factor receptor; gefitinib; glucocorticoid; osimertinib; acrylamide derivative; aniline derivative; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; osimertinib; adult; algorithm of drug causality for epidermal necrolysis score; blister; cancer recurrence; cancer staging; case report; clinical article; computer assisted tomography; dermatitis; disease severity; drug withdrawal; EGFR gene; epiphora; face injury; female; follow up; gene mutation; genital injury; histopathology; human; human tissue; in vitro study; Letter; limb injury; lung adenocarcinoma; medical history; middle aged; mouth ulcer; priority journal; rash; scoring system; skin biopsy; Stevens Johnson syndrome; wedge resection; wound care; adverse drug reaction; genetics; lacrimal fluid; lung tumor; mutation; non small cell lung cancer; pathology; Stevens Johnson syndrome; ulcer; Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Stevens-Johnson Syndrome; Tears; Ulcerletter10.1016/j.lungcan.2018.12.030306128192-s2.0-85062087200